|
|
|
|
Update on managing acute pericarditis
In a patient with chest pain, differentiating between an MI and pericarditis is critical. Once pericarditis is identified, the management focuses on preventing recurrent pericardial pain.
|
| |
More>>
|
|
|
|
|
|
Incretin hormones in the treatment of type 2 diabetes
Type 2 diabetes mellitus is a progressive disease affecting more than 18 million Americans. Incretin mimetics and DPP-IV inhibitors are new classes of antihyperglycemic agents that may improve glycemic control in patients with type 2 diabetes. The incretin hormone, glucagon-like peptide 1 (GLP-1), stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric motility. GLP-1 levels are decreased in type 2 diabetes.
|
| |
More>>
|
|
|
|
|
|
How to get your high-risk patients to the new NCEP goals
Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL, consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can help a significantly greater proportion of your patients attain their lipid goals.
|
| |
More>>
|
|
|
|
|
|
New drug may reduce need for transfusions in MDS
Celgene Corp., Summit, N.J., recently received Food & Drug Administration approval for lenalidomide (Revlimid) for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
|
| |
More>>
|
|
|
